INDBInternet News Database 2.5 Updated just now · 297 sources Show or hide images Light or dark

Local Ablative Therapy Shows Promise in Oligoprogressive NSCLC

Save Like Comments Compare coverage

Summary

Local ablative therapy alone is linked to a median 11 months of progression-free survival in oligoprogressive non-small cell lung cancer after durvalumab. Medscape News UK

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    Local Ablative Therapy Shows Promise in Oligoprogressive NSCLC

    Local ablative therapy alone is linked to a median 11 months of progression-free survival in oligoprogressive non-small cell lung cancer after durvalumab. Medscape News UK

Comments

Comments need JavaScript.